Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;9(1):52-58.
doi: 10.1007/s13193-017-0718-2. Epub 2017 Dec 8.

Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience

Anish Jacob Cherian  1 , Pooja Ramakant  1 , Rekha Pai  2 , Marie Therese Manipadam  3 , S Elanthenral  3 , Anuradha Chandramohan  4 , Julie Hephzibah  5 , David Mathew  5 , Dhukabandhu Naik  6 , Thomas V Paul  6 , Simon Rajaratnam  6 , Nihal Thomas  6 , M J Paul  1 , Deepak Thomas Abraham  1
Affiliations

Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience

Anish Jacob Cherian et al. Indian J Surg Oncol. 2018 Mar.

Abstract

We conducted this study to evaluate the demography, clinical presentation, management and outcomes of medullary thyroid carcinoma (MTC) from the Indian context. This was a retrospective study of patients with MTC managed between January 2008 and December 2016. All pertinent data was collected and the results were analysed using STATA (v.13.1). MTC accounted for 90/2022 (4.45%) patients managed with thyroid cancer during the study period. The mean age of presentation was 40 years (range 14-70 years) with 47 males and 43 females. The most common presentation included goitre with cervical lymphadenopathy seen in 60 patients (66.7%). There were 11 patients (12.2%) with systemic metastasis at presentation. Rearranged during transfection (RET) testing was performed in 71 patients and was positive in 25 (35.2%). The mutations among these patients were seen in the following codons: 634 (12), 804 (8), 790 (3) and 618 (2). Persistent hypercalcitoninemia (calcitonin > 50 pg/ml) was observed in 62/80 (77.5%) patients. Forty patients underwent a meta-iodo-benzyl-guanidine (MIBG) scan in the postoperative period, 10 were positive. The mean duration of follow-up was 32 months and 10 patients defaulted from follow-up. Sixteen patients developed metastasis during the period of follow-up while eight patients expired. The mean survival was 85.75 months (95% CI 78.7-92.7). MTC accounted for 4.5% of thyroid carcinomas in this cohort among which 35% were hereditary. Persistent hypercalcitoninemia following surgery is seen in more than 70% of patients but this does not affect survival. RET screening should be performed for all patients with MTC as curative surgery can be offered for mutation positive offspring.

Keywords: Calcitonin; Medullary thyroid carcinoma; RET; Thyroid carcinoma.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsAll authors declare that they have no conflict of interest.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Figures

Fig. 1
Fig. 1
Scatter plot depicting the postoperative calcitonin values
Fig. 2
Fig. 2
Comparing the overall survival analysis between normal postop calcitonin and postoperative hypercalcitoninemia
See this image and copyright information in PMC

References

    1. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc. 2015;25(6):567–610. doi: 10.1089/thy.2014.0335. - DOI - PMC - PubMed
    1. Allen SM, Bodenner D, Suen JY, Richter GT. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma. Laryngoscope. 2009;119(7):1303–1311. doi: 10.1002/lary.20299. - DOI - PubMed
    1. Rowland KJ, Moley JF. Hereditary thyroid cancer syndromes and genetic testing. J Surg Oncol. 2015;111(1):51–60. doi: 10.1002/jso.23769. - DOI - PubMed
    1. Pai R, Nehru GA, Samuel P, Paul MJ, Thomas N, Premkumar JA, Hephzibah J, Shanthly N, Oommen R, Nair A, Seshadri MS, Rajaratnam S. Mutational analysis of RET proto-oncogene among patients with medullary thyroid carcinoma and ‘at risk’ carriers from India. Clin Endocrinol. 2011;75(4):571–572. doi: 10.1111/j.1365-2265.2011.04069.x. - DOI - PubMed
    1. Nosé V. Familial thyroid cancer: a review. Mod Pathol. 2011;24:S19–S33. doi: 10.1038/modpathol.2010.147. - DOI - PubMed

LinkOut - more resources